September 29, 2016 4:12 PM ET

Healthcare Providers and Services

Company Overview of New York Blood Center, Inc.

Company Overview

New York Blood Center, Inc. operates as a community-based nonprofit blood collection and distribution organization in the United States. It offers blood products, including red blood cells, plasma products, platelet products, frozen blood and washed products, whole blood, granulocytes, autologous and directed blood donation, and HEMACORD, a FDA approved allogeneic cord-blood derived hematopoietic stem cell therapy product; and clinical trials management solutions, such as protocol review and revision, medical and technical consultation, IRB review at NYBC or central IRB, study execution and oversight at NYBC, inspection/audit preparation/participation at NYBC, research pharmacy services, and...

310 East 67th Street

New York, NY 10065

United States

Founded in 1964

Phone:

212 570-3050

Fax:

212 570-3466

Key Executives for New York Blood Center, Inc.

Chief Executive Officer, President and Trustee
Chief Financial Officer and Senior Vice President
Chief Operating Officer and Senior Vice President
Chief Information Officer and Vice President
Vice President, General Counsel and Secretary
Compensation as of Fiscal Year 2016.

New York Blood Center, Inc. Key Developments

Innovative Blood Resources and New York Blood Center Join Forces in Lifesaving Mission

Innovative Blood Resources (IBR) and New York Blood Center (NYBC) announced that they are combining their operations to create one of the nation's leading blood centers, serving patients and hospitals in the Northeast, Midwest and nationally. The combination of the strengths of IBR and NYBC provides the opportunity for greater breadth of services, efficiency and financial stability. The goal is to continue to provide the high level of blood and hematology related products and services in a fast-changing environment for community blood centers nationwide. The new partnership with IBR comes on the heels of NYBC's highly successful 2014 alliance with Community Blood Center of Greater Kansas City (CBC).

New York Blood Center Announces New Collaboration with the University of California, Davis to Manufacture Specialized Lines of Stem Cells

New York Blood Center (NYBC) announced a new collaboration with the University of California, Davis, Health System to manufacture specialized lines of stem cells as potential therapies for repair and regeneration of retina, kidney, lung and liver tissue, as well as for the treatment of neurodegenerative disorders such as Parkinson's, Alzheimer's and Huntington's disease. Under the two-year agreement, UC Davis will produce induced pluripotent stem cells (iPSCs) from homozygous units from New York Blood Center's umbilical cord blood bank. Cord blood units contain adult stem cells collected from umbilical cord blood donations after the birth and safe delivery of a baby. NYBC's rare collection of homozygous units presents a unique opportunity to make iPSC lines that will be capable of making any human tissue and being matched to a large number of people. This will allow for vast new opportunities for future clinical use.

New York Blood Center Partners with UC Davis Health System to Produce More Viable Stem Cell Therapies

New York Blood Center (NYBC) announced a new collaboration with the University of California, Davis, Health System to manufacture specialized lines of stem cells as potential therapies for repair and regeneration of retina, kidney, lung and liver tissue, as well as for the treatment of neurodegenerative disorders such as Parkinson's, Alzheimer's and Huntington's disease. The new collaboration, through NYBC's Milstein Cord Blood Center, is funded by the Howard and Abby Milstein Foundation. Under the two-year agreement, UC Davis will produce induced pluripotent stem cells (iPSCs) from homozygous units from New York Blood Center's umbilical cord blood bank. Cord blood units contain adult stem cells collected from umbilical cord blood donations after the birth and safe delivery of a baby. NYBC's rare collection of homozygous units presents a unique opportunity to make iPSC lines that will be capable of making any human tissue and being matched to a large number of people. This will allow for vast new opportunities for future clinical use.

Similar Private Companies By Industry

Company Name Region
@ Home Medical, Inc. United States
@home approach, llc United States
@Home Care United States
1011 E. Pecan Grove Road, LLC United States
1125 Sir Francis Drake Boulevard Operating Company, Llc United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact New York Blood Center, Inc., please visit nybloodcenter.org. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.